Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

beta-thioguanine deoxyriboside

A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication. This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo. Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:beta thioguanine deoxyriboside
Abbreviation:B-TGDR
BTG
Chemical structure:1,9-dihydro-6H-purine-6-thione, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)
2'-deoxythioguanosine
2'-desoxy-6-thioguanosine
6-mercaptoguaninedeoxyriboside
9H-purine-6-thiol, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl) monohydrate
beta-2'-deoxy-6-thioguanosine
beta-2'-deoxythioguanosine
beta-2'-deoxythiol guanosine
thioguanine 9-.beta-D-2'-deoxyriboside
thioguanine 9-beta-D-2'-deoxyriboside
IND number:6874
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search